Rafiq Hasan, Complement Therapeutics CEO

VCs 'Com­ple­men­t' Eu­ro­pean biotech with $79M for reti­nal AAV gene ther­a­py tri­al next year

Com­ple­ment Ther­a­peu­tics raised a €72 mil­lion ($79.6 mil­lion) Se­ries A to bankroll a Phase Ib of its AAV gene ther­a­py in ge­o­graph­ic at­ro­phy.

The dis­ease, which leads to blind­ness, gots its first ap­proved treat­ment this year via Apel­lis’ Syfovre. Iver­ic Bio is close be­hind.

Like those drug de­vel­op­ers, the UK and Ger­man start­up is go­ing af­ter the com­ple­ment cas­cade, thought to con­tribute to mul­ti­ple dis­eases. In­stead of fre­quent in­jec­tions, Com­ple­ment wants a one-and-done gene ther­a­py to thwart the on­set of blind­ness, and the biotech will test that ap­proach start­ing in Sep­tem­ber or Oc­to­ber 2024, CEO and man­ag­ing di­rec­tor Rafiq Hasan told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.